Kinnate Biopharma sells exarafenib to Pierre Fabre Laboratories
PremiumThe FlyKinnate Biopharma sells exarafenib to Pierre Fabre Laboratories
8M ago
Kinnate Biopharma price target raised to $2.59 from $1.50 at Stifel
Premium
The Fly
Kinnate Biopharma price target raised to $2.59 from $1.50 at Stifel
9M ago
Kinnate Biopharma downgraded to Market Perform from Outperform at William Blair
Premium
The Fly
Kinnate Biopharma downgraded to Market Perform from Outperform at William Blair
9M ago
Pyxis Oncology announces appointment of Kobayashi as CMO
PremiumThe FlyPyxis Oncology announces appointment of Kobayashi as CMO
12M ago
Kinnate Biopharma reports Q3 EPS (65c), consensus (67c)
Premium
The Fly
Kinnate Biopharma reports Q3 EPS (65c), consensus (67c)
1y ago
Dell upgraded, Starbucks downgraded: Wall Street’s top analyst calls
Premium
The Fly
Dell upgraded, Starbucks downgraded: Wall Street’s top analyst calls
1y ago
Kinnate Biopharma trading resumes
PremiumThe FlyKinnate Biopharma trading resumes
1y ago
Kinnate Biopharma to reduce workforce by 70%, announces reprioritization plan
Premium
The Fly
Kinnate Biopharma to reduce workforce by 70%, announces reprioritization plan
1y ago
Kinnate Biopharma trading halted, news pending
Premium
The Fly
Kinnate Biopharma trading halted, news pending
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100